176 related articles for article (PubMed ID: 29420220)
1. BQ323636.1, a Novel Splice Variant to
Gong C; Man EPS; Tsoi H; Lee TKW; Lee P; Ma ST; Wong LS; Luk MY; Rakha EA; Green AR; Ellis IO; Lam EW; Cheung KL; Khoo US
Clin Cancer Res; 2018 Aug; 24(15):3681-3691. PubMed ID: 29420220
[No Abstract] [Full Text] [Related]
2. SpliceArray profiling of breast cancer reveals a novel variant of NCOR2/SMRT that is associated with tamoxifen resistance and control of ERα transcriptional activity.
Zhang L; Gong C; Lau SL; Yang N; Wong OG; Cheung AN; Tsang JW; Chan KY; Khoo US
Cancer Res; 2013 Jan; 73(1):246-55. PubMed ID: 23117886
[TBL] [Abstract][Full Text] [Related]
3. KPNA1 regulates nuclear import of NCOR2 splice variant BQ323636.1 to confer tamoxifen resistance in breast cancer.
Tsoi H; Man EP; Leung MH; Mok KC; Chau KM; Wong LS; Chan WL; Chan SY; Luk MY; Cheng CN; Khoo US
Clin Transl Med; 2021 Oct; 11(10):e554. PubMed ID: 34709749
[No Abstract] [Full Text] [Related]
4. Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen.
Brechbuhl HM; Finlay-Schultz J; Yamamoto TM; Gillen AE; Cittelly DM; Tan AC; Sams SB; Pillai MM; Elias AD; Robinson WA; Sartorius CA; Kabos P
Clin Cancer Res; 2017 Apr; 23(7):1710-1721. PubMed ID: 27702820
[No Abstract] [Full Text] [Related]
5. Loss of Estrogen-Regulated
Zhang W; Wu M; Chong QY; Zhang M; Zhang X; Hu L; Zhong Y; Qian P; Kong X; Tan S; Li G; Ding K; Lobie PE; Zhu T
Cancer Res; 2018 Sep; 78(17):4915-4928. PubMed ID: 29945962
[TBL] [Abstract][Full Text] [Related]
6. Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study.
Hjorth CF; Nielsen AS; Sørensen HT; Lash TL; Damkier P; Hamilton-Dutoit S; Cronin-Fenton D
Acta Oncol; 2019 Feb; 58(2):168-174. PubMed ID: 30458661
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer.
Tsoi H; Shi L; Leung MH; Man EPS; So ZQ; Chan WL; Khoo US
Life (Basel); 2022 Jan; 12(1):. PubMed ID: 35054486
[TBL] [Abstract][Full Text] [Related]
8. CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.
van Agthoven T; Sieuwerts AM; Veldscholte J; Meijer-van Gelder ME; Smid M; Brinkman A; den Dekker AT; Leroy IM; van Ijcken WF; Sleijfer S; Foekens JA; Dorssers LC
Br J Cancer; 2009 Dec; 101(11):1824-32. PubMed ID: 19904269
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
10. SRSF5 Regulates the Expression of BQ323636.1 to Modulate Tamoxifen Resistance in ER-Positive Breast Cancer.
Tsoi H; Fung NN; Man EPS; Leung MH; You CP; Chan WL; Chan SY; Khoo US
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190199
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
Allred DC; Anderson SJ; Paik S; Wickerham DL; Nagtegaal ID; Swain SM; Mamounas EP; Julian TB; Geyer CE; Costantino JP; Land SR; Wolmark N
J Clin Oncol; 2012 Apr; 30(12):1268-73. PubMed ID: 22393101
[TBL] [Abstract][Full Text] [Related]
12. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
[TBL] [Abstract][Full Text] [Related]
13. Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer.
Wu X; Zahari MS; Renuse S; Nirujogi RS; Kim MS; Manda SS; Stearns V; Gabrielson E; Sukumar S; Pandey A
Mol Cell Proteomics; 2015 Nov; 14(11):2887-900. PubMed ID: 26330541
[TBL] [Abstract][Full Text] [Related]
14. Cholesterol Depletion Modulates Drug Resistance Pathways to Sensitize Resistant Breast Cancer Cells to Tamoxifen.
Henriques Palma GB; Kaur M
Anticancer Res; 2022 Jan; 42(1):565-579. PubMed ID: 34969766
[TBL] [Abstract][Full Text] [Related]
15. Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer.
Thewes V; Simon R; Schroeter P; Schlotter M; Anzeneder T; Büttner R; Benes V; Sauter G; Burwinkel B; Nicholson RI; Sinn HP; Schneeweiss A; Deuschle U; Zapatka M; Heck S; Lichter P
Cancer Res; 2015 Feb; 75(4):720-31. PubMed ID: 25643697
[TBL] [Abstract][Full Text] [Related]
16. The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers.
Kastrati I; Joosten SEP; Semina SE; Alejo LH; Brovkovych SD; Stender JD; Horlings HM; Kok M; Alarid ET; Greene GL; Linn SC; Zwart W; Frasor J
Mol Cancer Res; 2020 Jul; 18(7):1018-1027. PubMed ID: 32245803
[TBL] [Abstract][Full Text] [Related]
17. Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence.
Smith CL; Migliaccio I; Chaubal V; Wu MF; Pace MC; Hartmaier R; Jiang S; Edwards DP; Gutiérrez MC; Hilsenbeck SG; Oesterreich S
Breast Cancer Res Treat; 2012 Nov; 136(1):253-65. PubMed ID: 23015261
[TBL] [Abstract][Full Text] [Related]
18. Which women decide to take tamoxifen?
Narod SA; Sopik V; Sun P
Breast Cancer Res Treat; 2017 Jul; 164(1):149-155. PubMed ID: 28374324
[TBL] [Abstract][Full Text] [Related]
19. Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance.
Takahashi M; Hayashida T; Okazaki H; Miyao K; Jinno H; Kitagawa Y
Cancer Sci; 2014 Jun; 105(6):675-82. PubMed ID: 24698107
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen Resistance Trumped and Oral Selective Estrogen Receptor Degraders Arrive.
Jordan VC
Clin Cancer Res; 2018 Aug; 24(15):3480-3482. PubMed ID: 29674510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]